Emcure Pharmaceuticals Limited has named C. S. Muralidharan as an Additional Director, Non-Executive and Independent, and as an Independent Director for an initial three-year term, with effect from 1 April 2026. The Board approved the move at its meeting on March 9, 2026, with the appointment subject to the approval of the members. The company highlighted that Mr. Muralidharan is not debarred from holding office by SEBI or any other authority and that he is not related to any director or KMP of the company.
Mr. C. S. Muralidharan brings about four decades of corporate experience across hydrocarbons and pharmaceutical sectors, having held board and senior leadership positions across India, Asia and Europe. His track record encompasses strategy, M&A, enterprise risk management, capital restructuring, transformation and ESG initiatives. Notably, he served as Group Chief Financial Officer at Sun Pharmaceutical Industries Limited, among other positions at Indian Oil Corporation Limited, Ranbaxy, Lupin, Matrix Laboratories, Watson Group, and more.
A Cost & Management Accountant by training, Mr. Muralidharan also holds a Master’s degree in Commerce and completed the Executive Program in General Management from the Booth School of Business, University of Chicago. The disclosure notes that he is not related to any director or KMP and his appointment is expected to bolster governance and strategic oversight as Emcure navigates a dynamic pharmaceutical landscape.
The development underscores Emcure’s ongoing emphasis on strengthening its board with seasoned leadership to guide growth, governance and long-term value creation for shareholders.